體外實驗發(fā)現(xiàn)槐定堿能濃度相關(guān)地抑制大腸癌LS174t細(xì)胞、SW620細(xì)胞、SW480細(xì)胞、HCT-116細(xì)胞，胃癌BGC823細(xì)胞、MGC-803細(xì)胞、SGC7901細(xì)胞、MKN45細(xì)胞、MKN28細(xì)胞，胰腺癌capan-1細(xì)胞，肝癌97H細(xì)胞、Bel細(xì)胞、HepG2細(xì)胞，食管癌EC109細(xì)胞，食管胃交界腺癌OE-19細(xì)胞、SK-GT2細(xì)胞，白血病K562細(xì)胞、HL60細(xì)胞，淋巴瘤U937細(xì)胞，骨髓瘤NS-1細(xì)胞，乳腺癌MCF-7細(xì)胞，卵巢癌PM-2細(xì)胞、SKVO3細(xì)胞，宮頸癌HeLa細(xì)胞，肺癌A549細(xì)胞、NCI細(xì)胞，DMS153細(xì)胞，黑素瘤A375細(xì)胞，舌鱗癌TCA8113細(xì)胞，神經(jīng)膠質(zhì)瘤U87細(xì)胞、U87MG細(xì)胞，前列腺癌PC3細(xì)胞增殖。整體實驗發(fā)現(xiàn)槐定堿抑制SW480細(xì)胞、HCT-116細(xì)胞，白血病L1210細(xì)胞，肺癌Lewis細(xì)胞，肉瘤S180細(xì)胞、S37細(xì)胞、W256細(xì)胞、EAC細(xì)胞移植瘤在小鼠或大鼠體內(nèi)生長。臨床上槐定堿已被試用于治療惡性滋養(yǎng)細(xì)胞腫瘤、消化道腫瘤、惡性淋巴瘤，有開發(fā)成抗腫瘤新藥的潛力。

Sophoridine inhibits proliferation in association with dosage on large intestine carcinoma LS174t cells, SW620 cells, SW480 cells, HCT-116 cells, and gastric carcinoma BGC823 cells, MGC-803 cells, SGC7901 cells, MKN45 cells, MKN28 cells, and pancreatic cancer capan-1 cells, and hepatoma 97H cells, Bel cells, HepG2 cells, and carcinoma of esophagus EC109 cells, and esophagogastric junctional adenocarcinoma OE-19 cells, SK-GT2 cells, and leukemia K562 cells, HL-60 cells, and lymphoma U937 cells, and myeloma NS-1 cells, and mammary cancer MCF-7 cells, and ovarian carcinoma PM-2 cells, SKOV3 cells, and cervical carcinoma HeLa cells, and lung cancer A549 cells, NCI cells, DMS153 cells, and melanoma A375 cells, squamous carcinoma of tongue TCA8113 cells, neuroglioma U87 cells, U87MG cells, and prostatic carcinoma PC3 cells, in vitro. Sophoridine has the effect in inhibiting transplant growth of SW480 cells, HCT-116 cells, and leukemia L1210 cells, and lung cancer Lewis cells, sarcoma S180 cells, S37 cells, W256 cells, EAC cells in mice or rats. In clinic, sophoridine has been tried to treat for malignant choriocarcinoma, digestive system tumors, and malignant lymphoma, so it has the potential to develop new anti-tumor drugs.

R285.5